中国免疫学杂志2011，Vol.27Issue(4)：360-362,3.DOI:10.3969/j.issn.1000-484X.2011.04.017
DC-CIK细胞治疗中晚期恶性肿瘤531例分析
Analysis of effects of DC-CIK cells therapy on 531 patients of middle and advanced stage carcinoma
摘要
Abstract
Objective :To assess the therapeutic effects of DC-CIK cells immun-otherapy on middle and advanced stage of carcinoma .Methods :The therapeutic effects and side effects of DC-CIK cells immunothemrpy on middle and advanced stage carcinoma after operation ,chemotherapy and radiotherapy was reviewed .Results :After the treatment ,the Ag-NORs rised from 5.16％ to 5.68％ ,89 .8％ of the patients ' KPS rised over 20 score,objective response rate (OR) was 47 .8％ ,clinicalbenefit rate (CBR)was 93.3％ .The 3-year survival rate was 61. 2％ .The DC-CIK cells had no adverse influence on the heart function ,liver function ,renal functionand blood routine .Conclusion :DC-CIK cells are safe and valid on middle and advanced stage carcinoma .They can enhance immune function ,ameliorate lifequality and increase 3-year survival rate.关键词
树突状细胞/细胞因子激活的杀伤细胞/恶性肿瘤分类
医药卫生引用本文复制引用
鲍锋,盛春华,杨光..DC-CIK细胞治疗中晚期恶性肿瘤531例分析[J].中国免疫学杂志,2011,27(4):360-362,3.基金项目
文为吉林省科技发展计划重点项目(No.20090466) （No.20090466）
